| |
|
|
-
| Diabetes Care 1999 Jun;22(6):913-9 |
|
Konjac-mannan (glucomannan)
improves glycemia and other associated risk factors for coronary
heart disease in type 2 diabetes. A randomized controlled metabolic
trial.
Vuksan V, Jenkins DJ, Spadafora P, Sievenpiper JL, Owen R,
Vidgen E, Brighenti F, Josse R, Leiter LA, Bruce-Thompson C.
Department of Nutritional Sciences, St. Michael's Hospital,
Faculty of Medicine, University of Toronto, Ontario, Canada.
v.vuksan@utoronto.ca
OBJECTIVE: To examine whether Konjac-mannan (KJM) fiber improves
metabolic control as measured by glycemia, lipidemia, and blood
pressure in high-risk type 2 diabetic patients. RESEARCH DESIGN
AND METHODS: A total of 11 hyperlipidemic and hypertensive type
2 diabetic patients treated conventionally by a low-fat diet
and drug therapy participated. After an 8-week baseline, all
were randomly assigned to take either KJM fiber-enriched test
biscuits (0.7 g/412 kJ [100 kcal] of glucomannan) or matched
placebo wheat bran fiber biscuits during two 3-week treatment
phases separated by a 2-week washout period. The diet in either
case was metabolically controlled and conformed to National
Cholesterol Education Program Step 2 guidelines, while medications
were maintained constant. Efficacy measures included serum fructosamine,
lipid profiles, apolipoproteins, blood pressure, body weight,
and nutritional analysis. RESULTS: Compared with placebo, KJM
significantly reduced the metabolic control primary end points:
serum fructosamine (5.7%, P = 0.007, adjusted alpha = 0.0167),
total:HDL cholesterol ratio (10%, P = 0.03, adjusted alpha =
0.05), and systolic blood pressure (sBP) (6.9%, P = 0.02, adjusted
alpha = 0.025). Secondary end points, including body weight,
total, LDL, and HDL cholesterol, triglycerides, apolipoproteins
A-1, B, and their ratio, glucose, insulin, and diastolic blood
pressure, were not significant after adjustment by the Bonferroni-Hochberg
procedure. CONCLUSIONS: KJM fiber added to conventional treatment
may ameliorate glycemic control, blood lipid profile, and sBP
in high-risk diabetic individuals, possibly improving the effectiveness
of conventional treatment in type 2 diabetes.
Publication Types:
- Clinical Trial
- Randomized Controlled Trial
|
|
|